Course Experts: Abigail Horan, PharmD

Course Description: This courses evaluates pivotal trials for FDA-approved emerging therapies for acute myeloid leukemia (AML) and identifies adverse drug reactions in AML treatment. It reviews treatment with menin inhibitors and general clinical pearls when generating treatment for patients with AML.